Damora Therapeutics Inc.

DMRA | NASDAQ

Price Alert Chart Builder DCF Calculator

$22.20

-$0.65 (-2.84%)

Sep 22, 2026, 2:33 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $1.41B

Enterprise Value $865.98M

Beta 1.47

Average Volume 506.47K

Shares Outstanding (Diluted) 61.14M

Shares Change YoY 4522.51%

Institutional Ownership N/A

Exchange NASDAQ

ISIN KYG2646Y1044

Price Performance

Price Change 1M -25.7%

Price Change 3M -0.4%

Price Change 6M -8.8%

Price Change YTD 4.8%

Price Change 1Y 4.8%

Price Change 3Y -21.5%

Price Change 5Y -21.5%

1M CAGR (ann.) -23.6%

1Y CAGR (ann.) 696.2%

5Y CAGR (ann.) -26.6%

All-Time CAGR -37.8%

Valuation

PE Ratio -0.18

Forward PE N/A

PEG Ratio 0.00

Forward PEG -0.06

PS Ratio N/A

Forward PS N/A

PB Ratio 2.73

P/FCF Ratio -33.57

P/Adj. FCF Ratio -33.19

P/OCF Ratio -33.12

EV/Sales N/A

EV/EBIT -3.25

EV/EBITDA -3.25

EV/FCF -20.67

Earnings Yield -546.1%

FCF Yield -3.0%

Adj. FCF Yield -3.0%

Financial Health

Net Cash $540.52M

Total Debt $0

Cash & Short-Term Investments $540.52M

Total Assets $543.64M

Current Ratio 19.73

Quick Ratio 19.73

Debt / Equity Ratio 0.00

Debt / EBITDA -0.00

Debt / FCF -0.00

OCF / Debt N/A

Interest Coverage 0.00

Altman Z-Score 28.72

Piotroski F-Score 4

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -1.1%

Returns

Return on Assets -48.4%

Return on Equity -82.6%

Return on Invested Capital -52.4%

Return on Capital Employed -52.4%

Return on Tangible Assets -48.4%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y -94.2%

EPS CAGR 5Y -17.4%

EPS CAGR 10Y N/A

FCF CAGR 3Y 4.4%

FCF CAGR 5Y 36.8%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 3

EPS Growth Next 3Y 32.7%

Revenue Growth Next 3Y N/A

Earnings Date Nov 4, 2026

EPS Estimate (next Q) -$0.52

EPS Growth Est (next Q) -78.0%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $43.75

Price Target Upside 91.5%

Cash Flow

Operating Cash Flow $-41.9M

Free Cash Flow $-41.9M

Adj. Free Cash Flow $-42.38M

FCF Per Share -$0.69

OCF Per Share -$0.69

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-79K

Operating Income $-270.66M

EBITDA $-266.46M

Net Income $-262.83M

EPS (Diluted) -$124.78

Revenue / Employee N/A

Profit / Employee $-37.55M

Employees 7